Psoriatic arthritis;Arthritis psoriatica (Psoriasisarthritis)

Journal fur Mineralstoffwechsel

Volumn 12, Issue 4, 2005, Pages 105-109

  Feyertag, J ^a   Dunky, A ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CELECOXIB; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HEREDITY; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PSORIATIC ARTHRITIS; RADIODIAGNOSIS; REVIEW;

EID: 30944469171     PISSN: 10237763     EISSN: 16809408     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl 2): ii14-7.
2. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27: 1247-50.
3. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978; 53: 511-8.
4. Brockbank J, Schentag C, Rosen C et al. Psoriatic arthritis (PSA) is common among patients with psoriasis and family medicine clinic attendees. Arthritis Rheum 2001; 44: S94.
5. Salonen S. The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations (poster). In: Spring Symposium of the European Academy of Dermatology and Venerology; Malta, 2003.
6. Helliwell PS, Wright V. PsA: clinical features. In: Klippel JH, Dieppe PA (eds). Rheumatology. Mosby, London, 1998; 6.21.1-6.21.8.
7. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2004; 16: 338-43.
8. Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis: multivariate relative risk model. Arthritis Rheum 1995; 38: 845-50.
9. Williamson L, Dockerty JL, Dalbeth N, McNally E, Ostlere S, Wordsworth BP. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford) 2004; 43: 85-8.
10. Rahman P, Bartlett S, Siannis F, Pellett FJ, Farewell VT, Peddle L, Schentag CT, Alderdice CA, Hamilton S, Khraishi M, Tobin Y, Hefferton D, Gladman DD. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 2003; 73: 677-81.
11. Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003; 48: 1408-13.
12. Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del Rio J, Rodriguez Perez A, Brantbar C, Lopez-Larrea CL. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999; 42: 1010-6.
13. Grubic Z, Peric P, Eeeuk-Jelicic E, Zunec R, Stingl K, Curkovic B, Kerhin-Brkljacic V. The MICA-A4 triplet repeats polymorphism in the transmembrane region confers additional risk for development of psoriatic arthritis in the Croatian population. Eur J Immunogenet 2004; 31: 93-8.
14. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169: 2818 -22.
15. Fearon U, Veale DJ. Pathogenesis of psoriatic arthritis. Clin Exp Dermatol 2001; 26: 333-7.
16. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, FitzGerald OM: Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001; 166: 2878-86.
17. Wright V. Rheumatism and psoriasis; a re-evaluation. Am J Med 1959; 27: 454-62.
18. Baker H, Golding DN, Thompson M. Psoriasis and arthritis. Ann Intern Med 1963; 58: 909-25.
19. Blumberg BS, Bunim JJ, Calkins E, Pirani CL, Zvaifler NJ. ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 1964; 26: 93-7.
20. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
21. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987; 62: 127-41.
22. Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol (Stockh) 1989; 146 (Suppl): 69-71.
23. Helliwell P, Marchesoni A, Peters M, Barker M, Wright V. A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991; 30: 339-45.
24. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245-50.
25. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33: 834-9.
26. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994; 33: 133-8.
27. Fournie B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V, Ginesty E, Andrieu V, Dromer C, Fournie A. Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed 1999; 66: 446-56.
28. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089-93.
29. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-6.
30. Brockbank J, Stein M, Schentag C, Gladman DD. Characteristics of dactylitis in psoriatic arthritis (PsA). J Rheumatol 2001; 28 (suppl 6): 1416.
31. Gladman DD, Strand V, Mease PJ, Antoni C, Nash P, Kavanaugh A. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005; 64 (suppl II): ii 115-6.
32. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987; 62: 127-41.
33. Gladman DD. Clinical aspects of the spondyloarthropathies. Am J Med Sci 1998; 316: 234-8.
34. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13: 586-92.
35. Mathies U. Diagnose und Klassifikationskriterien der Osteoarthropathia psoriatica. In: Wollina U, Hein G, Kopf B (Hg.). Psoriasis und Gelenkerkrankungen. Gustav Fischer Verlag, Jena, 1996; 113-24.
36. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19: S17-S20.
37. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968; 80: 771-93.
38. Rahman P, Gladman DD, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998; 25: 1957-61.
39. Combe B, Goupille P, Kuntz J, Tebib J, Leote F, Bregeon C. Sulphasalazine in psoriatic arthritis; a randomized multicentre placebo controlled trial. Br J Rheumatol 1996; 35: 664-8.
40. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20.
41. Black RL, O'Brien WM, VanScott EJ, Aurbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964; 189: 743-7.
42. Fachinformation Methotrexat .,Lederle", Wyeth-Lederle Pharma, Wien, Österreich, Dezember 2004.
43. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998; 53: 20-6.
44. Liang GC, Barr WG. Long term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001; 44: S121.
45. Scarpa R, Manguso F, Oriente F, Peluso R, Oriente P. Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum 2001; 44: S92.
46. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50: 1939-50.
47. Fachinformation Arava® (Leflunomid) 10-mg-Filmtabletten, Aventis Pharma Deutschland, Frankfurt, Dezember 2004.
48. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
49. Fachinformation Enbrel® (Etanercept), Wyeth Europa, Maidenhead Berkshire, Großbritannien, Mai 2004.
50. Antoni C, Kavanaugh A, Kirkham B et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum 2002; 46 (Suppl 9): S381.
51. Fachinformation Remicade® (Infliximab), Centocor, Leiden, Niederlande, Jänner 2005.
52. Mease P, Gladman DD, Ritchlin C, Ruderman E, Steinfeld D, Choy E et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 2004; 50: 4097.
53. Fachinformation Humira® (Adalimumab), Abbott Laboratories, Kent, Vereinigtes Königreich, Juli 2004.
54. Ruderman E, Markenson J. Granulomatous infections and tumor necrosis factor antagonist therapies: update through June. Arthritis Rheum 2002; 48 (Suppl 9): S241.
55. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure. Circulation 2004; 109: 1594-602.
56. Devos SA, Van den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388-90.
57. Cohen M. RA therapy with biologics: safety and long-term considerations. In: Schiff M (ed). Rheumatology Educational Initiative (REDI): making a difference in rheumatology. Veritas Institute for Medical Education, Hasbrouck Heights, New Jersey, 2004; 137-60.